https://www.selleckchem.com/products/ABT-869.html
To investigate the feasibility and acceptability of using liraglutide 3.0mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis. A double-blind, randomized, placebo-controlled pilot trial took place in mental health centres and primary care within Southern Health NHS Foundation Trust. The participants were adults with schizophrenia, schizoaffective or first-episode psychosis prescribed antipsychotic medication who were overweight or obese. The intervention
Like
Comment
Share
